Get startedLog in
    Picture of Innovent Biologics logo

    1801 — Innovent Biologics News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapHigh Flyer
    All News

    Brief: Hutchmed (China) Says Frusica-2 Phase II/III Study Met Primary Endpoint

    Picture of Innovent Biologics logoInnovent Biologics
    19/03/2025 01:18
    March 19 (Reuters) - HUTCHMED (China) 0013.HK:

FRUSICA-2 PHASE II/III STUDY OF FRUQUINTINIB & SINTILIMAB COMBINATION MET PRIMARY ENDPOINT IN CHINA

Further company coverage: 0013.HK

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Innovent Biologics

    See all news